In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma

David J. Verbik, Warren W. Stinson, Michael J. Brunda, Anne Kessinger, Shantaram S Joshi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Despite considerable advancement in anticancer therapy, minimal residual disease (MRD) is still a major problem in the clinical management of cancer, including lymphoma. In this report, we have studied the antitumor effects of interleukin-12 (IL-12) against an aggressive liver metastatic murine RAW117-H10 lymphoma Our results using three different doses of IL-12 (0.175, 0.35 and 0.7 μg/mouse) showed that a 0.35 μg dose is the most efficacious against lymphoma grown in intact mice. Furthermore, we have evaluated the therapeutic effects of IL-12 against residual lymphoma in a transplantation setting. BALB/c mice were treated with high-dose therapy (HDT) and transplanted with syngeneic bone marrow cells added with a known number of RAW117-H10 lymphoma cells to mimic the clinical situation of MRD. The mice were then treated with IL-12 (0.25 μg/mouse/day) alone or IL-12 plus activated cytotoxic effector cells. Our results showed that IL-12 had a significant (P < 0.05) antitumor therapeutic effect against liver metastatic lymphoma grown in intact mice as well as in lymphoma-bearing mice treated with HDT followed by stem cell transplantation as determined by survival period. The therapeutic effect of IL-12 was also demonstrated by a very significant decrease (P < 0.05) in the tumor burden in livers from the IL-12-treated mice. Mice that were treated with IL-12 following HDT and hematopoietic stem cell transplantation had a significant decrease in circulating white blood cells (P < 0.05), a significant increase in spleen weight and cellularity (P < 0.05), and hematopoietic progenitor cells (P < 0.05), a significant increase in the number of splenocytes expressing IL-2 α-chain receptor (P < 0.05), and an increase in the frequency of natural killer cells in their spleens. These studies suggest that cytokines such as IL-12 may have the potential to mediate antitumor effects against residual lymphoma without compromising lymphohematopoietic recovery.

Original languageEnglish (US)
Pages (from-to)219-229
Number of pages11
JournalClinical and Experimental Metastasis
Volume14
Issue number3
StatePublished - Aug 7 1996

Fingerprint

Therapeutic Uses
Interleukin-12
Lymphoma
Residual Neoplasm
Liver
Spleen
Interleukin-2 Receptors
Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Therapeutics
Hematopoietic Stem Cells
Tumor Burden
Natural Killer Cells
Bone Marrow Cells
Leukocytes
Transplantation
Cytokines
Weights and Measures

Keywords

  • Antitumor effects
  • Immune augmentation
  • Interleukin-12
  • Residual lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. / Verbik, David J.; Stinson, Warren W.; Brunda, Michael J.; Kessinger, Anne; Joshi, Shantaram S.

In: Clinical and Experimental Metastasis, Vol. 14, No. 3, 07.08.1996, p. 219-229.

Research output: Contribution to journalArticle

Verbik, David J. ; Stinson, Warren W. ; Brunda, Michael J. ; Kessinger, Anne ; Joshi, Shantaram S. / In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. In: Clinical and Experimental Metastasis. 1996 ; Vol. 14, No. 3. pp. 219-229.
@article{71f0b5666a444d938014c59f34f02692,
title = "In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma",
abstract = "Despite considerable advancement in anticancer therapy, minimal residual disease (MRD) is still a major problem in the clinical management of cancer, including lymphoma. In this report, we have studied the antitumor effects of interleukin-12 (IL-12) against an aggressive liver metastatic murine RAW117-H10 lymphoma Our results using three different doses of IL-12 (0.175, 0.35 and 0.7 μg/mouse) showed that a 0.35 μg dose is the most efficacious against lymphoma grown in intact mice. Furthermore, we have evaluated the therapeutic effects of IL-12 against residual lymphoma in a transplantation setting. BALB/c mice were treated with high-dose therapy (HDT) and transplanted with syngeneic bone marrow cells added with a known number of RAW117-H10 lymphoma cells to mimic the clinical situation of MRD. The mice were then treated with IL-12 (0.25 μg/mouse/day) alone or IL-12 plus activated cytotoxic effector cells. Our results showed that IL-12 had a significant (P < 0.05) antitumor therapeutic effect against liver metastatic lymphoma grown in intact mice as well as in lymphoma-bearing mice treated with HDT followed by stem cell transplantation as determined by survival period. The therapeutic effect of IL-12 was also demonstrated by a very significant decrease (P < 0.05) in the tumor burden in livers from the IL-12-treated mice. Mice that were treated with IL-12 following HDT and hematopoietic stem cell transplantation had a significant decrease in circulating white blood cells (P < 0.05), a significant increase in spleen weight and cellularity (P < 0.05), and hematopoietic progenitor cells (P < 0.05), a significant increase in the number of splenocytes expressing IL-2 α-chain receptor (P < 0.05), and an increase in the frequency of natural killer cells in their spleens. These studies suggest that cytokines such as IL-12 may have the potential to mediate antitumor effects against residual lymphoma without compromising lymphohematopoietic recovery.",
keywords = "Antitumor effects, Immune augmentation, Interleukin-12, Residual lymphoma",
author = "Verbik, {David J.} and Stinson, {Warren W.} and Brunda, {Michael J.} and Anne Kessinger and Joshi, {Shantaram S}",
year = "1996",
month = "8",
day = "7",
language = "English (US)",
volume = "14",
pages = "219--229",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma

AU - Verbik, David J.

AU - Stinson, Warren W.

AU - Brunda, Michael J.

AU - Kessinger, Anne

AU - Joshi, Shantaram S

PY - 1996/8/7

Y1 - 1996/8/7

N2 - Despite considerable advancement in anticancer therapy, minimal residual disease (MRD) is still a major problem in the clinical management of cancer, including lymphoma. In this report, we have studied the antitumor effects of interleukin-12 (IL-12) against an aggressive liver metastatic murine RAW117-H10 lymphoma Our results using three different doses of IL-12 (0.175, 0.35 and 0.7 μg/mouse) showed that a 0.35 μg dose is the most efficacious against lymphoma grown in intact mice. Furthermore, we have evaluated the therapeutic effects of IL-12 against residual lymphoma in a transplantation setting. BALB/c mice were treated with high-dose therapy (HDT) and transplanted with syngeneic bone marrow cells added with a known number of RAW117-H10 lymphoma cells to mimic the clinical situation of MRD. The mice were then treated with IL-12 (0.25 μg/mouse/day) alone or IL-12 plus activated cytotoxic effector cells. Our results showed that IL-12 had a significant (P < 0.05) antitumor therapeutic effect against liver metastatic lymphoma grown in intact mice as well as in lymphoma-bearing mice treated with HDT followed by stem cell transplantation as determined by survival period. The therapeutic effect of IL-12 was also demonstrated by a very significant decrease (P < 0.05) in the tumor burden in livers from the IL-12-treated mice. Mice that were treated with IL-12 following HDT and hematopoietic stem cell transplantation had a significant decrease in circulating white blood cells (P < 0.05), a significant increase in spleen weight and cellularity (P < 0.05), and hematopoietic progenitor cells (P < 0.05), a significant increase in the number of splenocytes expressing IL-2 α-chain receptor (P < 0.05), and an increase in the frequency of natural killer cells in their spleens. These studies suggest that cytokines such as IL-12 may have the potential to mediate antitumor effects against residual lymphoma without compromising lymphohematopoietic recovery.

AB - Despite considerable advancement in anticancer therapy, minimal residual disease (MRD) is still a major problem in the clinical management of cancer, including lymphoma. In this report, we have studied the antitumor effects of interleukin-12 (IL-12) against an aggressive liver metastatic murine RAW117-H10 lymphoma Our results using three different doses of IL-12 (0.175, 0.35 and 0.7 μg/mouse) showed that a 0.35 μg dose is the most efficacious against lymphoma grown in intact mice. Furthermore, we have evaluated the therapeutic effects of IL-12 against residual lymphoma in a transplantation setting. BALB/c mice were treated with high-dose therapy (HDT) and transplanted with syngeneic bone marrow cells added with a known number of RAW117-H10 lymphoma cells to mimic the clinical situation of MRD. The mice were then treated with IL-12 (0.25 μg/mouse/day) alone or IL-12 plus activated cytotoxic effector cells. Our results showed that IL-12 had a significant (P < 0.05) antitumor therapeutic effect against liver metastatic lymphoma grown in intact mice as well as in lymphoma-bearing mice treated with HDT followed by stem cell transplantation as determined by survival period. The therapeutic effect of IL-12 was also demonstrated by a very significant decrease (P < 0.05) in the tumor burden in livers from the IL-12-treated mice. Mice that were treated with IL-12 following HDT and hematopoietic stem cell transplantation had a significant decrease in circulating white blood cells (P < 0.05), a significant increase in spleen weight and cellularity (P < 0.05), and hematopoietic progenitor cells (P < 0.05), a significant increase in the number of splenocytes expressing IL-2 α-chain receptor (P < 0.05), and an increase in the frequency of natural killer cells in their spleens. These studies suggest that cytokines such as IL-12 may have the potential to mediate antitumor effects against residual lymphoma without compromising lymphohematopoietic recovery.

KW - Antitumor effects

KW - Immune augmentation

KW - Interleukin-12

KW - Residual lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0030059125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030059125&partnerID=8YFLogxK

M3 - Article

C2 - 8674276

AN - SCOPUS:0030059125

VL - 14

SP - 219

EP - 229

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 3

ER -